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AbstrAct
mTOR inhibition has emerged as a promising strategy for head and neck 
squamous cell carcinomas (HNSCC) treatment. However, most targeted therapies 
ultimately develop resistance due to the activation of adaptive survival signaling 
mechanisms limiting the activity of targeted agents. Thus, co-targeting key adaptive 
mechanisms may enable more effective cancer cell killing. Here, we performed a 
synthetic lethality screen using shRNA libraries to identify druggable candidates 
for combinatorial signal inhibition. We found that the ERK pathway was the most 
highly represented. Combination of rapamycin with trametinib, a MEK1/2 inhibitor, 
demonstrated strong synergism in HNSCC-derived cells in vitro and in vivo, including 
HNSCC cells expressing the HRAS and PIK3CA oncogenes. Interestingly, cleaved 
caspase-3 was potently induced by the combination therapy in PIK3CA+ cells in 
vitro and tumor xenografts. Moreover, ectopic expression of PIK3CA mutations into 
PIK3CA- HNSCC cells sensitized them to the pro-apoptotic activity of the combination 
therapy. These findings indicate that co-targeting the mTOR/ERK pathways may 
provide a suitable precision strategy for HNSCC treatment. Moreover, PIK3CA+ HNSCC 
are particularly prone to undergo apoptosis after mTOR and ERK inhibition, thereby 
providing a potential biomarker of predictive value for the selection of patients that 
may benefit from this combination therapy.
IntroductIon
Recent advances in RNAi technology have enabled 
synthetic lethal screenings in mammalian cells on a 
genome-wide scale [1]. Synthetic lethality, first described 
in yeast genetics, occurs when alteration of a gene results 
in change of the cellular phenotype only in the presence 
of another nonlethal genetic alteration. Recently, this 
approach has been applied to mammalian cells using 
RNAi screens [2, 3]. For example, RNAi screens in 
combination with active compounds were used for the 
identification of sensitizing targets and novel genetic 
interdependencies in cancer [4, 5]. RNAi screens can be 
carried out with either siRNA-based transient transfection 
or shRNA-based stable gene knockdown. Vector-based 
shRNA libraries have several unique advantages that make 
them particularly attractive: they can be screened in pools 
and this significantly reduces the cost of the screen; they 
afford long-term gene knockdown and thus can reveal 
slow phenotypic changes in the cell; and they can be 
readily adapted for in vivo screens in mouse models [1].
Head and neck squamous cell carcinomas (HNSCC) 
are among the ten cancers most frequently diagnosed 
each year in the United States, affecting approximately 
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42,000 new patients and resulting in approximately 8,300 
deaths [6]. Mammalian target of rapamycin (mTOR) 
is at the center of signaling pathways that are critical 
for the regulation of cellular metabolism, growth, and 
proliferation [7]. Recent findings indicate that multiple 
genetic and epigenetic alterations converge on the 
persistent activation of PI3K/AKT/mTOR signaling in 
most HNSCC lesions [8-13]. Specifically, activating 
mutations in the PI3K catalytic subunit α, encoded by the 
PIK3CA gene, is the most frequent oncogenic event in 
HNSCC, with 18.1 % of all HNSCC displaying PIK3CA 
mutations and 21.2 % of cases displaying PIK3CA gene 
copy number gain. In addition, HNSCC also have multiple 
genomic alterations, such as PTEN mutations (2.8 %) and 
gene copy number loss (31.0 %) and activating mutations 
in RAS (5.9 %) and AKT (2.2 %) genes that result in PI3K/
mTOR pathway activation. This cancer driver overreliance 
may in turn render HNSCC particularly sensitive to 
PI3K and mTOR inhibitors. Indeed, we and others have 
demonstrated this pathway dependence in a large series 
of genetically-defined and chemically-induced preclinical 
HNSCC experimental models by inhibiting mTOR with 
rapamycin and its analogs, which inhibit the activity of 
mTORC1 via binding to FKBP-12 and forming a ternary 
com plex with mTOR [14-18]. 
The use of rapamycin and rapalogs have validated 
the concept that the PI3K/AKT/mTOR pathway can 
be successfully targeted in clinical cancer treatment. 
In this regard, our recently completed clinical trial 
using rapamycin in newly diagnosed and previously 
untreated HNSCC patients has demonstrated promising 
clinical activity [19] in contrast to most tumor types 
in which rapalogs often have modest and highly 
variable responses [18]. However, most targeted agents 
promote the activation of adaptive cellular responses 
that ultimately render cancer lesions resistant to their 
antitumor effect [20]. Thus, the combinatorial use of 
mTOR inhibitors with other drugs interfering with 
these resistance mechanisms may represent a promising 
strategy to improve treatment efficacy. In order to identify 
new potential targets for combination treatment with 
mTOR inhibitors, we performed a synthetic lethality 
screen using a pooled shRNA library with rapamycin in 
HNSCC cells. We identified a synthetic lethal interaction 
between ERK pathway inhibition and rapamycin, and 
validated the synergism of the co-target treatment on the 
growth inhibition of HNSCC cells in vitro and in vivo. 
Furthermore, we found that HNSCC cells harboring 
PIK3CA mutations are particularly susceptible to undergo 
apoptosis upon mTOR and ERK inhibition, thus providing 
a new therapeutic option for PIK3CA+ HNSCC patients. 
results
An rnAi screens reveals synthetic lethal 
interactions with mtor inhibitors
We utilized a pooled retroviral shRNA library 
for the synthetic lethal screen [21]. We analyzed the 
change in relative abundance of each shRNA over 
time by sequencing of half-hairpin (HH) barcodes 
derived from the shRNA population to identify those 
that are antiproliferative and are thus depleted from the 
population. We compared the lethality signature of the 
cells in presence of rapamycin and control to identify 
those shRNAs showing selective depletion in the cells 
in presence of rapamycin but not in control (Figure 1A). 
We chose the HNSCC cell line HN12 [16] for the screen, 
as this HNSCC cell line carries no driver mutations 
endogenously [9], but, as most HNSCC-derived cells, 
exhibits elevated mTOR activity and it is sensitive to 
growth inhibition in response to rapamycin [14]. Target 
genes were defined as hits when the difference between 
log2 end/start ratio of rapamycin treated samples and that 
of control samples was ≤ −2. We identified 117 genes as 
hits, among which 22 encoded kinases (Figure 1B). This 
gene set was particularly enriched for kinases involved in 
ERK pathway signaling, including KSR1 (KSR1), CRAF/
RAF1 (RAF1), ERK (MAPK1) and RSK1 (RPS6KA1), 
which suggests that their depletion by shRNAs is 
synthetically lethal with rapamycin. We also performed 
gene ontology (GO) enrichment analysis and found the 
GO term “MAPK cascade” was significantly related to 
this gene set (P = 2.7E-8). These findings prompted us to 
explore the impact of ERK signaling inhibition in HNSCC 
cells in combination with rapamycin. As an approach, 
we took advantage that a selective MEK1/2 inhibitor 
trametinib, which blocks ERK activation, was recently 
approved for the treatment of unresectable or metastatic 
melanoma with BRAFV600E or BRAFV600K mutations by the 
US Food and Drug Administration as a monotherapy and 
in combination with dabrafenib [22]. 
In order to evaluate the effect of drug-drug 
interaction on cell viability, we performed a factorial dose 
matrix combinatorial drug treatment with rapamycin and 
trametinib. HN12 cells were incubated with these drugs 
in a 6 × 8 dose-response matrix and cell viability was 
measured after 72 hrs of treatment (Figure 1C). We also 
investigated whether the combination effect displayed a 
synergistic activity. For this purpose, the fraction affected 
(Fa) combination index (CI) plot (Fa-CI plot) curves were 
simulated using CompuSyn software [23]. CI at 0.5 of 
Fa was 0.14 and 0.10 for 1:4 and 1:16 constant ratio of 
rapamycin to trametinib respectively (Figure 1D). These 
data indicated a strong synergism of the combination 
therapy in HN12 cells. We next evaluated the effect of 
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Figure 1: rnAi synthetic lethal screen. A. Schema of shRNA screen. The change in the relative abundance of each shRNA in the 
library over time is measured using the normalized PD 13/PD 0 ratio of its reads. A log2 PD 13/PD 0 ratio of < 0 indicates the shRNA is 
depleted in the population over time, and a log2 PD 13/PD 0 ratio of ˃ 0 indicates the shRNA is enriched in the population. b. Hit kinase 
genes. Targets were filtered by log2 PD 13/PD 0 ratio of < −2 (n = 3). c. Factorial dose matrix combinatorial drug treatment. HN12 cells 
were incubated for 72 hrs with indicated concentrations of drugs. Numbers on the matrix indicate % Cell Viability (n = 3). d. Computer-
simulated Fa-CI curves were created based on the matrix data. The ratios of rapamycin : trametinib were indicated. Synergism (CI < 
1), additive effect (CI = 1), or antagonism (CI > 1) for the indicated levels of growth inhibition (Fraction affected) induced by the drug 
combination. e. mTOR/ERK pathway. HN12 cells were treated with 0.1% DMSO, 20nM rapamycin, 20nM trametinib or the combination 
for 24hrs.
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rapamycin and trametinib on the ERK and PI3K-mTOR 
signaling pathway in these HNSCC cells. For this purpose, 
cells were seeded in 6-well plates and harvested after 24h 
treatment, and samples were used for western blotting 
analysis. As expected, rapamycin decreased phospho-S6 
(pS6) and phospho-4E-BP1 (p4E-BP1) (Figure 1E). 
In contrast, phospho-AKT (pAKT) and phospho-ERK 
(pERK) were increased (Figure 1E). Instead, trametinib 
clearly decreased pERK, consistent with its MEK blocking 
activity, and of interest, trametinib also partially decreased 
pS6 (Figure 1E).
synergistic effects of the combination of 
rapamycin and trametinib on Hnscc harboring 
HRAS and PIK3CA mutations
HNSCC lesions often harbor activating mutations in 
PIK3CA (18.1 %), encoding the catalytic PI3K-α subunit 
and less frequent oncogenic mutants of the HRAS (5.6 
%) or KRAS (0.2 %) genes [8, 12], collectively referred 
herein as RAS. To explore whether the combination of 
rapamycin and trametinib also displays synergistic effect 
in HNSCC tumors harboring activating mutations of 
RAS and PIK3CA, we evaluated the impact of this drug 
Figure 2: synergistic effects of the combination of rapamycin and trametinib on Hnscc-derived cells harboring 
HrAs or PIK3cA mutations. A. Computer-simulated Fa-CI curves were created based on the factorial dose matrix combinatorial 
drug treatment. The ratios of rapamycin : trametinib were indicated. Synergism (CI < 1), additive effect (CI = 1), or antagonism (CI > 1) 
for the indicated levels of growth inhibition (Fraction affected) induced by the drug combination. b. mTOR/ERK signaling pathway. Cells 
were treated with 0.1% DMSO, 20nM rapamycin, 20nM trametinib or the combination for 24hrs. c. Immunoblot analysis for cleaved-
PARP and cleaved caspase-3. Cells were treated with 0.1% DMSO, 20nM rapamycin, 20nM trametinib or the combination for 24hrs.
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Figure 3: Antitumoral activity of the mtor erKcombination therapy with rapamycin and trametinib against 
Hnscc harboring HrAs or PIK3cA mutations. A. Antitumor efficacy of rapamycin, trametinib, and combination. Athymic 
nude mice were transplanted with HNSCC cells. Treatment was initiated when the tumor volume reached approximately 200 mm3. The 
tumor growth curves (left), tumor weights at the end of the single agent and combined treatments (middle) and pictures of representative 
tumors (right) are displayed. Data points represent mean values ± SE (n = 10 per each group). b. Representative tumor tissue sections (top) 
and quantification (bottom) stained for Ki67 (n = 6 per each group). Scale bars represent 100 µm. *P < 0.05, **P < 0.01, ***P < 0.001.
Oncotarget10701www.impactjournals.com/oncotarget
combination in HNSCC cells harboring endogenous 
oncogenic mutations. We used UM-SCC-17B, which has 
a HRAS Q61L mutant and Detroit 562 cells exhibiting the 
PIK3CA H1047R mutation. The combination of rapamycin 
and trametinib demonstrated strong synergism in growth 
inhibition of these cells (Figure 2A, Supplementary Figure 
S1A). We next evaluated the effect of the combination 
treatment in the downstream signaling pathway of RAS 
and PI3K in these cell lines. Rapamycin decreased pS6 
and p4E-BP1, but in contrast, pAKT and pERK were 
both increased (Figure 2B). Trametinib treatment clearly 
decreased pERK, and it also enhanced the rapamycin-
mediated decrease of pS6 and p4E-BP1 (Figure 2B). 
We also evaluated whether trametinib, rapamycin, or 
their combination can promote apoptosis as judged by 
the accumulation of cleaved caspase-3. Remarkably, we 
found that whereas these drugs alone have limited effect, 
the combination treatment induced a significant increase 
in apoptosis in PIK3CA mutant HNSCC cell line, Detroit 
562, but not in the HRAS mutant HNSCC cells UM-SCC-
17B (Figure 2C).
Antitumoral activity of the combination therapy 
with rapamycin and trametinib against Hnscc 
harboring HRAS or PIK3CA mutations
We next evaluated the antitumoral activity of the 
ERK-mTOR targeting combination therapy in vivo, using 
UM-SCC-17B and Detroit 562 HNSCC xenografts, 
which harbor endogenous activating HRAS and PIK3CA 
mutations, respectively. The combination therapy with 
rapamycin and trametinib was more effective than each 
of the single agents individually (Figure 3A). The body 
weight after 4 weeks treatment was 22.7±2.1 g in the 
combination treatment group and 23.7±0.7 g in vehicle 
control group. The antitumoral activity was reflected 
by a decreased immunohistochemical detection of 
nuclear Ki67, which was used for the evaluation of cell 
proliferation. The MEK-mTOR combination therapy 
showed significant reduction of HNSCC cells expressing 
nuclear Ki67 in both xenograft models (Figure 3B). 
Immunohistochemistry analysis of treated tumors 
revealed that trametinib enhanced the rapamycin-mediated 
inhibition of S6 and 4E-BP1 in vivo, and blunted the 
rapamycin-induced ERK activation in these HNSCC 
cells (Figure 4A, 4B). Consistent with the activation of 
ERK, rapamycin also induced elevated phospho-MEK1/2 
(pMEK1/2) levels. pMEK1/2 was increased by trametinib, 
likely as a feedback mechanisms stimulating the activation 
of MEK upstream kinases upon MEK inhibition by its 
direct blocker. AKT was activated by rapamycin in UM-
SCC-17B but not in Detroit 562 in vivo, suggesting that 
activation of the ERK pathway may represent a more 
general secondary effect of rapamycin than pAKT increase 
(Figure 4A). In addition, a clear distinction between these 
HNSCC cells was that cleaved caspase-3 was significantly 
increased by the combination therapy in Detroit 562 
(PIK3CA mutant) but not in UM-SCC-17B (HRAS mutant) 
(Figure 4C).
mtor and MeK inhibition display a synergistic 
growth inhibitory activity in Hnscc cells 
genetically engineered to express activating KRAS 
and PIK3CA mutations
Our observations suggested that mTOR and MEK 
co-targeting exerts a synergistic antiproliferative effect 
in HNSCC cells in vitro and in vivo, and a selective pro-
apoptotic impact on PIK3CA expressing HNSCC cells. 
However, cancer cells display an intrinsic heterogeneity, 
hence it is unclear if trametinib and rapamycin promote 
apoptosis in Detroit 562 because these cells express 
mutant PIK3CA or if this response is due to cell-dependent 
variations. As an approach to explore these possibilities, 
we next investigated whether a significant synergism was 
displayed in isogenic HNSCC cells, CAL27 cells, which 
were genetically engineered to express RAS and PIK3CA 
mutants [17]. Strong synergism was demonstrated 
between trametinib and rapamycin in wild type CAL27 
cells and in both KRAS and PIK3CA expressing CAL27 
cells, supporting that the drug combination is effective 
in HNSCC cells displaying multiple genetic alterations 
(Figure 5A, Supplementary Figure S1B). In this biological 
relevant system, PI3KCA expressing CAL27 cells showed 
significantly stronger synergism than CAL27 WT and 
CAL27 KRAS cells. Indeed, CI at ED50 was 0.09, 0.06 and 
0.01 for CAL27 WT, CAL27 KRAS and CAL27 PIK3CA 
cells, respectively (Figure 5A). 
We next evaluated the effect of rapamycin and 
trametinib in the downstream signaling pathway elicited 
by RAS and PI3K in these cells. As for other HNSCC 
cells, rapamycin decreased pS6 and p4E-BP1 in these 
cell lines. In contrast, pAKT and pERK were increased 
(Figure 5B). Trametinib clearly decreased pERK and 
enhanced the rapamycin-mediated reduction of pS6 and 
p4E-BP1 (Figure 5B). We also evaluated apoptosis by 
cleaved caspase-3 (Figure 5C). Rapamycin increased 
caspase-3 cleavage in CAL27 PIK3CA cells but failed to 
stimulate apoptosis in the CAL27 WT cell line. Trametinib 
also promoted a limited increase in cleaved caspase-3 in 
CAL27 KRAS, and this effect was much more remarkable 
in CAL27 PIK3CA cells (Figure 5C).
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Figure 4: effects of the combination of rapamycin and trametinib on mtor/erK signaling and apoptosis in Hnscc 
harboring HrAs or PIK3cA mutations. A. mTOR/ERK signaling pathway. Cells were transplanted into athymic mice and 
treated with vehicle, rapamycin, trametinib or combination for four days. Tumor lysates were analyzed with immunoblot analysis. b. 
Representative tumor tissue sections stained for pS6 and pERK. Scale bars represent 100 µm. c. Representative tumor tissue sections (top) 
and quantification (bottom) stained for cleaved-caspase 3 (n = 3 per each group). Scale bars represent 100 µm. *P < 0.05, **P < 0.01, ***P 
< 0.001.
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Antitumoral activity of the rapamycin and 
trametinib combination therapy in genetically 
engineered Hnscc cells expressing activating 
RAS or PIK3CA mutations
We next investigated whether the combination of 
rapamycin and trametinib was effective in the isogenic cell 
line panel CAL27 WT, CAL27 HRAS and CAL27 PIK3CA 
xenograft models. A more significant antitumoral effect 
was observed in the groups treated with the combination 
therapy than in the groups treated with single agents in 
each of these xenograft models (Figure 6A). This was 
reflected by decreased nuclear Ki67, a biomarker for cell 
proliferation, in the combination therapy compared to 
single agents (Figure 6B, Supplementary Figure S2A). 
To study the biochemical and biological effects of the 
drug combination in vivo in this isogenic HNSCC cell 
panel, we performed immunohistochemistry for pS6, 
pERK (Figure 7A) and cleaved caspase-3 (Figure 7B). 
Rapamycin mediated inhibition of pS6 was enhanced 
by the combination with trametinib (Figure 7A). ERK 
was activated by rapamycin in these cells, and strongly 
inhibited by the therapy with trametinib (Figure 7A). 
Figure 5: synergism of rapamycin and trametinib in genetically engineered Hnscc cells to express activating KrAs 
or PIK3cA mutations. A. Computer-simulated Fa-CI curves were created based on the factorial dose matrix combinatorial drug 
treatment. The ratios of rapamycin : trametinib were 1:16. Synergism (CI < 1), additive effect (CI = 1), or antagonism (CI > 1) for the 
indicated levels of growth inhibition (Fraction affected) induced by the drug combination (left). CI values at Fa = 0.5 was used to calculate 
the mean between experiments (n = 3). *P < 0.05, **P < 0.01. b. mTOR/ERK signaling pathway. Cells were treated with 0.1% DMSO, 
20nM rapamycin, 20nM trametinib or the combination for 0.5h or 24hrs. c. Immunoblot analysis for cleaved-caspase 3. Cells were treated 
with 0.1% DMSO, 20nM rapamycin, 20nM trametinib or the combination for 24hrs.
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Figure 6: Antitumoral activity of the rapamycin and trametinib combination therapy against genetically engineered 
Hnscc cells expressing KrAs and PIK3cA oncogenes. A. Antitumor efficacy of rapamycin, trametinib, and combination. 
Athymic nude mice were transplanted with HNSCC cells. Treatment was initiated when the tumor volume reached approximately 200 
mm3. The tumor growth curves (left), tumor weights at the end of the single agent and combined treatments (middle) and representative 
histological sections for each treatment group. Scale bars represent 5 mm (right) are displayed. Data points represent mean values ± SE (n = 
10 per each group). b. Representative tumor tissue sections (top) and quantification (bottom) stained for Ki67 (n = 6 per each group). Scale 
bars represent 100 µm. *P < 0.05, **P < 0.01, ***P < 0.001.
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Cleaved caspase-3 was significantly induced in the tumors 
treated with the combination therapy in CAL27 PIK3CA 
(Figure 7B). However, only minor pro-apoptotic effects 
were observed in CAL27 WT and CAL27 KRAS (Figure 
7B, Supplementary Figure S2B). These finding suggest 
that while co-targeting MEK and mTOR is effective for 
tumor reduction in all HNSCC models tested, PIK3CA 
expression specifically sensitizes HNSCC cells to the pro-
apoptotic activity of MEK and mTOR combined targeted 
treatment, thereby displaying increased response. 
dIscussIon
Our in vitro data demonstrated strong synergism of 
the combination treatment with rapamycin and trametinib 
against HNSCC -derived cells exhibiting quite distinct 
genomic alterations, including cells carrying endogenous 
and genetically engineered RAS or PIK3CA mutations. 
Furthermore, the co-targeting therapy demonstrated 
significant effect on tumor growth in all HNSCC xenograft 
models tested. Intriguingly, CAL27 engineered to express 
PIK3CA mutations displayed the strongest synergism in 
vitro. Furthermore, the combination treatment significantly 
induced cleaved-caspase 3 in HNSCC cell lines carrying 
PIK3CA mutation endogenously and when ectopically 
expressed. Thus, in the presence of PIK3CA mutations, 
adding MEK inhibitors to mTOR blockade causes a 
proapoptotic switch from cytostatic to cytotoxic, which 
has important beneficial therapeutic implications. 
The mechanism of this remarkable genotype-
specific drug interaction remains unclear. For example, 
the ERK pathway has profound effects on the regulation 
Figure 7: effects of the combination of rapamycin and trametinib on mtor/erK signaling and apoptosis in genetically 
engineered Hnscc cells KrAs and PIK3cA mutations. A. Representative tumor tissue sections stained for pS6 and pERK. 
Scale bars represent 100 µm. b. Representative tumor tissue sections (top) and quantification (bottom) stained for cleaved-caspase 3 (n = 3 
per each group). Scale bars represent 100 µm. *P < 0.05, **P < 0.01.
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of cell survival pathways by the post-translational 
phosphorylation of pro-apoptotic and apoptotic regulatory 
molecules, including BAD, BIM, Mcl-1, caspase 9 and 
Bcl-2 [24]. On the other hand, mTOR also possesses both 
pro-apoptotic and anti-apoptotic effects [25]. Activated 
S6K is capable of binding to mitochondrial membrane 
and phosphorylating the pro-apoptotic molecule BAD, 
rendering BAD inactive and promoting cell survival 
[26]. In line with these observations, mTOR inhibition 
can promote apoptosis in several cancer models [16, 27]. 
Conversely, several studies demonstrated that mTOR 
inhibition attenuates cytotoxic agent-induced apoptosis 
in malignant cells [28, 29]. The mTOR function on 
apoptosis appears to be dictated by cell type and its 
activation state as well as by the mutational status of its 
downstream targets including well known apoptosis-
regulatory proteins such p53, BAD and Bcl-2 [30]. 
Thus, the interplay between mTOR and ERK inhibition 
may have pro-apoptotic functions in restricted genetic 
contexts. In line with this possibility, recently, Hata et 
al. reported that the concomitant use of MEK and PI3K 
inhibitor lead to upregulation of PUMA and BIM, both 
of which were necessary for the induction of an apoptotic 
response in KRAS-mutant in another cancer type, non-
small cell lung cancer (NSCLC) [31, 32]. Certainly, the 
underlying reasons in HNSCC that an apoptotic response 
is only elicited in PIK3CA mutant cells is clearly clinically 
relevant, and its precise underlying mechanism warrants 
further investigation.
In the current study we identified 22 kinases whose 
suppression is synthetic lethal with rapamycin for therapy 
against HNSCC. These include KSR1 (KSR1), CRAF/
RAF1 (RAF1), ERK (MAPK1) and RSK1 (RPS6KA1), 
which are involved in the ERK signaling pathway, 
suggesting that interfering with ERK activation renders 
HNSCC cells more sensitive to mTOR inhibition. 
Indeed, we show here that co-targeting MEK and mTOR 
using FDA approved therapeutic agents, trametinib 
and rapamycin, respectively, exerts a synergistic anti-
proliferative and pro-apoptotic effect in all HNSCC cell 
lines tested irrespective of their quite distinct mutational 
genomic landscape [9]. Furthermore, we found that the 
combined drug therapy was much more effective in 
promoting tumor regression that any of the single agents 
alone, supporting that synthetic gene lethality screens 
can be exploited for the development of new therapeutic 
options for HNSCC treatment. 
In addition to the ERK pathway, we also identified 
p38 MAPK (MAPK14) and MAP3K2 (MAP3K2), 
which are involved in other MAPK pathways as co-
targeting candidates. Recently, we reported that p38 
MAPK functions as a positive regulator of HNSCC in 
the context of the tumor microenvironment, controlling 
cancer cell growth and tumor-induced angiogenesis 
and lymphangiogenesis [33]. We also identified kinases 
involved in PI3K/AKT pathway. Among these were SGK3 
(SGK3), ARK5/NUAK1 (NUAK1), and NDR2 (STK38L). 
For example, activation of SGK3 downstream of PIK3CA 
and INPP4B is required for 3D cell proliferation, invasive 
migration, and tumorigenesis in vivo [34]. Overexpression 
of ARK5 confers tolerance to glucose starvation, which 
is a stress that leads to a decrease in ATP and an increase 
in AMP [35]. Activated AKT stimulates cell invasion 
by phosphorylating ARK5 at Ser600 [35]. ARK5 has 
been also reported to act as a tumor invasion-associated 
factor through NDR2 during IGF-1 signaling [36]. We 
also identified FAK (PTK2) and HIPK2 (HIPK2) in our 
synthetic lethality screens. FAK promotes cell survival 
through kinase-dependent and kinase-independent 
mechanisms [37, 38]. Overall, these results suggest that 
several MAPK and PI3K/AKT pathway components and 
FAK, among others, may participate in adaptive response 
mechanisms promoting resistance to rapamycin in HNSCC 
cells. Hence, their knock down or pharmacological 
inhibition with small molecule inhibitors can be also 
considered for the future development of more effective 
combination therapies for HNSCC. 
Overall, our unbiased genetic screen revealed that 
co-targeting mTOR and ERK using FDA approved agents 
results in a remarkable synergistic interaction in HNSCC 
preclinical models. While the inhibition of the PI3K/
AKT/mTOR and ERK pathways has been investigated 
in other malignancies, the in vivo impact of this co-
targeting strategy for HNSCC has not been well validated. 
Indeed, in all HNSCC tumors tested, the combination of 
tramatinib and rapamycin caused a rapid tumor collapse, 
and was much more active than any of these agents alone. 
Furthermore, we now show that the concomitant inhibition 
of mTOR and MEK promotes the apoptotic demise 
of HNSCC cells specifically in tumors expressing the 
PIK3CA oncogene, the most frequently driver mutation 
in this cancer type [8, 12]. Thus, these findings will have 
significant clinical implications, as they define a new 
mechanism-based precision therapeutic approach for the 
treatment of HNSCC patients, and define PIK3CA as a 
suitable biomarker of heightened beneficial therapeutic 
response to the combined treatment.
MAterIAls And MetHods
cell lines, tissue culture and antibodies
Human head and neck cancer cell lines Cal27, 
Detroit 562, were from American Type Culture 
Collection; UM-SCC-17B cell line was from Thomas 
Carey, University of Michigan. Cells were cultured in 
Dulbecco’s modified Eagle’s medium with 10 % fetal 
bovine serum supplemented with antibiotics, 5 % CO2 at 
37 °C. All cell lines underwent DNA authentication by 
multiplex STR profiling (Genetica DNA Laboratories, 
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Inc. Burlington, NC) prior to the described experiments 
to ensure consistency in cell identity. Antibodies against 
AKT, pAKTS473, pAKTT308, ERK1/2, pERK1/2, S6, pS6, 
MEK1/2, pMEK1/2, 4E-BP1, non-p4E-BP1T46, p4E-
BP1T37/46, p4E-BP1S65, cleaved caspase-3, cleaved PARP, 
α-Tubulin-HRP, GAPDH were purchased from Cell 
Signaling Technology (Beverly, MA). Mouse anti-Ki67 
antibody was purchased from DAKO (Carpinteria, CA).
shrnA screening
shRNA screening was performed as described 
[21]. HN12 cells were infected with pools of retroviral 
shRNA at a representation of ~1,000 and a multiplicity of 
infection (MOI) of ~1. At day 3 post infection cells were 
selected with puromycin for an additional 3 days (1 µg/
ml) to remove the minority of uninfected cells. After that, 
cells where propagated in culture for 3 days and then an 
initial population-doubling 0 (PD 0) sample was taken. 
The rest of the population was divided in 6 groups, and 
3 groups where kept as a control and 3 where treated 
with rapamycin (100 nM). Cells where propagated in the 
presence or not of drug for an additional 12 doublings 
before the final, PD 13 sample was taken. For each 
passage a minimal representation of 1000 was maintained. 
The shRNA library contained 9,149 retroviral shRNAs 
targeting human kinases, phosphatases, genes involved 
in protein ubiquination, and genes implicated in cancer. 
The libraries where expressed using the retroviral vector 
MSCV-PM. For PD 0 and PD 13 samples, shRNA HH 
barcode was PCR-recovered from genomic samples and 
samples where sequenced to calculate abundance of the 
different shRNA probes. 
The change in the relative abundance of each shRNA 
in the library over time is measured using the normalized 
PD 13/PD 0 ratio of its reads. A log2 PD 13/PD 0 ratio 
of < 0 indicates the shRNA is depleted in the population 
over time, and a log2 PD 13/PD 0 ratio of ˃ 0 indicates the 
shRNA is enriched in the population. To identify shRNAs 
that are synthetically lethal with rapamycin, the mean log2 
PD 13/PD 0 ratios of the rapamycin treated cell triplicates 
were compared to that of the control triplicates to derive 
the log2 ratio difference. A p-value of the difference 
between the two triplicates was calculated using the 
t-test. Targets were filtered by the presence of at least 2 
different shRNAs for the same gene and a P < 0.05. GO 
enrichment analysis was performed with ToppGene Suite 
software[39].
cell growth assays and drug combination analysis
Alamar Blue Cell Viability Reagent was purchased 
from Life Technologies. (Grand Island, NY) Cells were 
cultured in 96-well-plate and treated with drugs for 72 
hours. The manufacturer’s instructions were followed to 
complete the assay. Drug synergy was determined by the 
combination index methods using CompuSyn software 
[23]. CI values less than 1, equal to 1, and greater than 
1 represent synergism, additivity, and antagonism, 
respectively. 
Immunoblot analysis
The cells and the tissues were lysed in RIPA buffer 
containing Halt protease and phosphatase inhibitor 
cocktail (Thermo Scientific, Rockford, IL). Protein 
concentration was measured by Bio-Rad Protein Assay 
(Bio-Rad, Hercules, CA). Equal amounts of total proteins 
were subjected to SDS-polyacrylamide gel electrophoresis 
and transferred to PVDF membranes. Membranes were 
blocked with 5% nonfat dry milk in T-TBS buffer (50 mM 
Tris/HCl, pH 7.5, 0.15 M NaCl, 0.1% [v/v] Tween-20) 
for 2 h, and then incubated with primary antibodies 
in blocking buffer at 4 °C overnight. Detection was 
conducted by incubating the membranes with horseradish 
peroxidase-conjugated goat anti-rabbit IgG secondary 
antibody (Southern Biotech, Birmingham, AL) was used 
at a dilution of 1:50,000 in 5 % milk-T-TBS buffer, at 
room temperature for 1 h, and visualized with Immobilon 
Western Chemiluminescent HRP Substrate (Millipore, 
Billerica, MA).
tissue analysis
 All samples were fixed in zinc formalin (Z-Fix, 
Anatech) and embedded in paraffin; 5 µm sections 
were stained with Hematoxylin-Eosin for diagnostic 
purposes. For immunohistochemistry (IHC) studies the 
sections were deparaffinized, hydrated through graded 
ethanols, and the endogenous peroxidase inhibited with 
3 % H2O2 in 70 % ethanol. The slides were extensively 
washed with distilled water and antigen retrieval was 
performed by high temperature treatment with 10 mM 
citric acid in a microwave. After washing with water and 
PBS, the slides were successively incubated with the 
primary and secondary antibodies, and the ABC reagent 
(Vector Laboratories, Burlingame, CA). The reaction 
was developed with 3-3’-diamonobenzifdine under 
microscopic control. A Mouse on Mouse (M.O.M.) Basic 
Kit (Vector Laboratories, Burlingame, CA) was used in 
Ki67 staining to inhibit binding of secondary antibodies 
to mouse tissue.
In vivo mouse experiments and analysis
All the mice studies were carried out according to 
National Institutes of Health (NIH) approved protocols 
(ASP #13-695) in compliance with the NIH Guide for 
the Care and Use of Laboratory Mice. To establish tumor 
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xenografts, cells were transplanted into the flanks of 
athymic nude mice (female, four to six weeks old) (Harlan 
Laboratories, Inc., Indianapolis, IN), and when the tumor 
volume reached approximately 200 mm3, the mice were 
randomized into groups and treated by intraperitoneal 
injection (ip) with trametinib (1 mg/kg/day) and rapamycin 
(5 mg/kg/day), or control diluent (n = 10 per each group). 
Tumor volume was calculated by using the formula length 
× width × width/2. The mice were euthanized at the 
indicated time points and tumors isolated for histologic 
and immunohistochemical evaluation.
data and statistical analysis
Data were analyzed using GraphPad Prism version 
6 (GraphPad Software, San Diego, CA). Comparisons 
between experimental groups were made using unpaired t 
test. P < 0.05 was considered to be statistically significant. 
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